Gilead’s Remdesivir improves clinical outcomes in COVID-19 patients
Category: #health  By Pankaj Singh  Date: 2020-06-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Gilead’s Remdesivir improves clinical outcomes in COVID-19 patients

The novel coronavirus outbreak, which led to the on-going COVID-19 pandemic, has affected over five million people and taken the lives of over 300 thousand worldwide. But unfortunately, researchers have not been able to find treatment for this highly contagious disease yet.

However, several vaccines and drugs for the same are at a different levels of development and trial. Recently, Gilead Sciences, Inc., the American biopharmaceutical company, has announced that its investigational antiviral remdesivir can speed up the recovery of COVID-19 patients.  

According to sources, the outcomes of the company’s Phase 3 SIMPLE trial in hospitalized patients with modest COVID-19 pneumonia suggests that patients who received 5-day remdesivir treatment were 65% more likely to have clinical improvement at Day 11. This open-label clinical trial assessed 5-day and 10-day treatment courses of the remdesivir plus standard of care against the standard of care alone. 

Sources cite that the outcomes of a clinical trial with a 10-day treatment course of remdesivir versus standard of care also showed positive results but did not reach statistical significance. Remdesivir was well-tolerated in both the 5-day and 10-day treatment groups. The common adverse events occurring in over 5 percent of patients in both treatment groups were diarrhea, nausea, and headache.

The company is planning to submit the complete data for publication in a peer-reviewed journal in the forthcoming time.

Speaking on which, Francisco Marty, MD, Associate Professor of Medicine at Harvard Medical School said that these clinical outcomes offer supplementary encouraging data for remdesivir, indicating that a 5-day treatment course in early stages of COVID-19 can considerably improve the clinical outcomes for these patients.

Remdesivir is presently approved in Japan as a treatment for patients with COVID-19. However, outside of Japan, remdesivir is an unapproved drug. The U.S FDA ( Food and Drug Administration) has approved remdesivir for emergency use for treating hospitalized patients with severe COVID-19.

Source Credit- https://www.businesswire.com/news/home/20200601005310/en/Gilead-Announces-Results-Phase-3-Trial-Remdesivir



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...